| |
| |
|
| Insider
Information: |
Orloff John J |
| Relationship: |
EVP, Research & Develo... |
| City: |
Deerfield |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
0 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Baxalta Inc |
BXLT |
See Remarks |
2016-06-03 |
0 |
2015-07-01 |
0 |
Premium* |
|
|
Alexion Pharmaceuticals Inc |
ALXN |
EVP, Research & Develo... |
2021-07-21 |
0 |
2017-06-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
22 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2021-07-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(146,511) |
0 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2021-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
60,144 |
146,511 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2021-06-08 |
4 |
D |
$177.00 |
$346,389 |
D/D |
(1,957) |
86,367 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2021-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
24,473 |
88,324 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2020-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
40,677 |
85,206 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2020-12-16 |
4 |
D |
$157.96 |
$3,379,554 |
D/D |
(21,395) |
63,811 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2020-12-15 |
4 |
A |
$93.53 |
$3,741 |
D/D |
40 |
63,851 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2020-06-08 |
4 |
D |
$114.61 |
$319,074 |
D/D |
(2,784) |
44,529 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2020-03-02 |
4 |
D |
$90.54 |
$126,394 |
D/D |
(1,396) |
47,275 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
10,880 |
48,671 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2019-12-15 |
4 |
A |
$93.86 |
$3,567 |
D/D |
38 |
47,313 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2019-06-07 |
4 |
D |
$118.61 |
$330,447 |
D/D |
(2,786) |
37,791 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,428 |
40,577 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2019-02-28 |
4 |
D |
$132.92 |
$89,721 |
D/D |
(675) |
31,115 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2018-12-15 |
4 |
A |
$93.01 |
$3,162 |
D/D |
34 |
31,149 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2018-06-08 |
4 |
S |
$118.53 |
$250,691 |
D/D |
(2,115) |
31,790 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,940 |
33,905 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2017-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
24,965 |
24,965 |
0 |
- |
|
| BXLT |
Baxalta Inc |
See Remarks |
• – – |
2016-06-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(96,384) |
0 |
0 |
- |
|
| BXLT |
Baxalta Inc |
EVP and President, R&D |
• – – |
2016-03-03 |
4 |
D |
$39.30 |
$55,334 |
D/D |
(1,408) |
96,009 |
0 |
- |
|
| BXLT |
Baxalta Inc |
EVP and President, R&D |
• – – |
2016-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
55,951 |
97,417 |
0 |
- |
|
| BXLT |
Baxalta Inc |
See Remarks |
• – – |
2015-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
40,521 |
40,521 |
0 |
- |
|
22 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
